Feng Gao, MD

• Professor of Medicine
• Member of the Duke Human Vaccine Institute

https://medicine.duke.edu/faculty/feng-gao-md

A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia allergy treatment review cheap 5 mg desloratadine with visa. Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia allergy medicine eye generic desloratadine 5 mg with visa. Abnormal computed tomography brain scans in children with acute lymphoblastic leukemia: serial long-term follow-up quercetin allergy treatment buy cheap desloratadine on line. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries allergy medicine generic list purchase genuine desloratadine online. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia allergy forecast georgetown texas desloratadine 5 mg buy overnight delivery. Neuropsychological effects of cranial irradiation in young children with acute lymphoblastic leukemia 9 months after diagnosis. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy­a Pediatric Oncology Group study. Reduced incidence of the somnolence syndrome after prophylactic cranial irradiation in children with acute lymphoblastic leukemia. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Model for the development of scientific methodology for clinical therapeutic research in cancer. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukemia. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. Transfusion management strategies: a survey of practicing pediatric hematology/oncology specialists. Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia. Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia. Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Effect of chemotherapeutic treatment on the nutritional state and its repercussion on the therapeutic response of patients with acute lymphoblastic leukemia with standard risk]. Fitness of children with standard-risk acute lymphoblastic leukemia during maintenance therapy: response to a home-based exercise and nutrition program. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse. Lineage heterogeneity in acute leukaemia: acute mixed-lineage leukaemia and lineage switch. Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoietic stem cell transplantation with donor lymphocyte transfusion and interferon-alpha-2b. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Bone marrow transplant indications for childhood leukemias: achieving a consensus. Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer­Childhood Leukemia Cooperative Group. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. Significance of blasts in low-cell-count cerebrospinal fluid specimens from children with acute lymphoblastic leukemia. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. Testicular leukemic relapse: rate of regression and persistent disease after radiation therapy. Leydig cell function in boys following treatment for testicular relapse of acute lymphoblastic leukemia. Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Pulsatile growth hormone secretion in children with acute lymphoblastic leukemia after 1800 cGy cranial radiation. Neuroendocrine function in survivors of childhood acute lymphocytic leukemia and non-Hodgkins lymphoma: a study of pulsatile growth hormone and gonadotropin secretions. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. Disturbance in bone turnover in children with a malignancy at completion of chemotherapy. Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia. Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility. Evaluation of gonadal function following long-term treatment for acute lymphoblastic leukemia in girls. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. Parotid carcinoma as a second malignancy after treatment of childhood acute lymphoblastic leukemia. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy. Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Chapter 20 Acute Myeloid Leukemia, Myeloproliferative and Myelodysplastic Disorders Todd M. Smith the term myeloid includes all of the cells belonging to the granulocytic (neutrophilic, eosinophilic, basophilic), monocytic/macrophage, erythroid, megakaryocytic, and mast cell lineages. Myeloid malignancies result from abnormalities in genes that control cellular proliferation, survival, and differentiation. Myeloproliferative disorders are characterized by the excessive proliferation of relatively normally differentiated hematopoietic cells. These differences are reflected in the morphology, cytogenetics, and clinical presentation of the two distinct age groups. For example, adults often present with a more indolent disease course characterized by an isolated anemia and associated with del(5q) chromosome. Not surprisingly, myeloid neoplasms share common etiologies, which will be discussed here Table 20. Primary and Secondary Myeloid Neoplasms A neoplasm can arise in a previously healthy child and is conformingly named " de novo" or "primary. It is to be recognized, however, that among the children with so-called "primary" neoplasms, some may have an underlying, yet unknown, predisposing genetic defect. Therefore, the distinction between primary and secondary disease may become arbitrary. The multiplicity of reported malformations is considerable although no consistent pattern is evident. Isochromosome 7q may represent a separate entity with a long stable clinical course. If the affected identical twin developed leukemia as an infant, the concordance rate is almost 100%. One plausible reason for the age discrepancy is that following initiation of leukemia in one twin fetus, clonal progeny spreads to the co-twin via vascular anastomoses within a single, monochorionic placenta. When this occurs, the leukemia usually arises within weeks to months in the second twin.

The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation allergy shots san diego desloratadine 5 mg order with mastercard. Methotrexate levels in the interstitial space and seminiferous tubule of rat testis allergy shots for horses desloratadine 5 mg order. Occult abdominal involvement with apparently isolated testicular relapse in children with acute lymphocytic leukemia allergy testing madison wi desloratadine 5 mg buy otc. Testicular relapse in childhood acute lymphocytic leukemia during bone marrow remission allergy shots effects on immune system purchase desloratadine 5 mg online. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States allergy zucchini buy desloratadine with amex, 1981­2005. Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis­a Pediatric Oncology Group Study. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91­01. Acute lymphoblastic leukemia in infants: evidence for B cell origin of disease by use of monoclonal antibody phenotyping. Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Use of clinical and laboratory features to define prognostic subgroups in Bprecursor acute lymphoblastic leukemia: experience of the Pediatric Oncology Group. Good steroid response in vivo predicts a favorable outcome in children with Tcell acute lymphoblastic leukemia. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Cytoreduction and prognosis in acute lymphoblastic leukemia­the importance of early marrow response: report from the Childrens Cancer Group. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Status of minimal residual disease testing in childhood haematological malignancies. Does weight for height have prognostic significance in children with acute lymphoblastic leukemia Malnutrition in childhood lymphoblastic leukemia: a predictor of early mortality during the induction-to-remission phase of the treatment. I: Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. The magnitude of maintenance chemotherapy as a prognostic factor in the survival of patients with standard-risk acute lymphoblastic leukemia]. Longitudinal assessment of nutritional status in children treated for acute lymphoblastic leukaemia in Cuba. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. The mechanism of induction of complete remission in acute myeloblastic leukemia in man. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia. Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. An experimental therapeutic approach to L1210 leukemia in mice: combined chemotherapy and central nervous system irradiation. The analysis of these leukemias has shed light on the natural history of the disease. Frequently, affected individuals are syndromic with associated inherited genetic predispositions. The reason for this phenomenon is most likely that the intensification of treatment has led to greater exposure to genotoxic chemotherapy or radiation therapy. A large number of polymorphisms in genes involved in detoxification of chemotherapeutic agents have been identified. This enzyme catalyzes the S-methylation of thiopurines, including 6mercaptopurine and 6-thioguanine. These abnormal cells are the result of a variety of distinct genetic mutations that confer a proliferative and survival advantage due to their effect on differentiation, apoptosis, and self-renewal. These chromosomal abnormalities are heterogeneous and include aberrations such as gains or losses of whole chromosomes, structural abnormalities, or balanced translocations. Many of these genetic rearrangements can be linked to clinical outcomes and will be discussed later in the chapter. In fact, up to 45% of patients with a normal karyotype possess genetic abnormalities that are associated with clinical features of the disease and are often powerful prognostic indicators of outcome. Class I mutant genes exert their effect through aberrant activation of signal transduction pathways. However, it is not known for certain whether mutations occur in the most primitive hematopoietic stem cells or whether the mutations occur in a more differentiated stem cell, which then acquires the feature of self-renewal. With the development of refined staining techniques, followed by microscopy and histochemical staining by the mid-20th century, this distinction was possible. As chemotherapy became increasingly effective, these investigators stressed the importance of a more accurate recording of the distribution of cases entered into clinical trials. Although the classification of neoplasms should take into account all available information -morphology, cytochemistry, immunophenotype, genetics, and clinical features-it has taken a number of years to achieve a comprehensive system. As there is little evidence for lowering the blast count to 20%, a pediatric approach has been developed to rely not only on blast count but also to consider clinical features and cytogenetics. Progenitors that differentiate along the erythroid lineage express glycophorin A, which is a helpful marker in the diagnosis of acute erythroblastic leukemia (M6). False-positive results using these cell surface proteins can occur when platelets adhere to the surface of blasts. In particular, flow cytometry may reveal diagnostic criteria strongly indicative of a commitment to one lineage but with aberrant expression of antigens of another lineage. These criteria provided practitioners with a reproducible method of lineage assignment; however, there were flaws in this classification system. Among the drawbacks to this method were controversial "weighting" of some markers and the fact that abnormal molecular genetics were not considered. Ignoring these important diagnostic features often resulted in the arbitrary mixing of biologically distinct leukemias under the same label. In the current classification, only a limited number of antigens are used in defining the pattern of lineage involvement. Cytogenetics A complete cytogenetic analysis of leukemia cells is essential during initial evaluation to establish the diagnosis and risk classification, and to help to define the biology of the disease140,141,142,143 Table 20. Repeated analyses are recommended as needed after diagnosis for judging the response to therapy or for detecting genetic evolution. The primary approach is conventional karyotyping, which can demonstrate chromosomal number (ploidy) and structural changes such as amplifications, deletions, translocations, or inversions. Additional genetic studies should be guided by the results of the initial karyotype and by the diagnosis suspected based on the clinical, morphologic, and immunophenotypic studies. Cases with increased marrow basophils may have recurrent cytogenetic abnormalities, including deletions and translocations at 12p and t(6;9). The t(8;21) translocation usually occurs in this subtype with a frequency of 10% to 15%. The cytoplasmic granules may be so large that they totally obscure the nuclear/cytoplasmic margin. The hypogranular variant has a paucity or absence of granules and a predominantly bilobed nuclear shape. Another useful tool in the diagnosis is the fact that there are usually a high number (5 × 109/L) of peripheral monocytes. This variant is strongly associated with alterations of chromosome 16, most commonly inv(16) (16q22). The morphologic appearance of these abnormal eosinophils is most evident at the promyelocyte and myelocyte stages. The granules are often large, purple-violet in color, and often so dense that they obscure the cell morphology. This represents a proliferation of immature cells committed exclusively to the erythroid lineage; these cells comprise more than 80% of marrow cells. Morphologically the megakaryoblasts usually have a round, irregular, or indented nucleus, fine chromatin, and one to three nucleoli. Occasionally, the blasts are smaller with a low nucleus-to-cytoplasm ratio, resembling L2 lymphoblasts. In infants expressing the t(1;22) translocation, examination may reveal a stromal pattern of marrow infiltration mimicking a metastatic tumor. Patients may present with minimal symptoms associated with anemia or with life-threatening complications due to leukemic infiltration resulting in organ dysfunction or failure. A diagnosis is suggested by a complete blood cell count that demonstrates pancytopenia and peripheral blasts visible on a peripheral smear. These electrolyte abnormalities are the result of renal tubular dysfunction caused by lysozyme released from leukemic cells. However, patients are at high risk for bacterial infections because of a low number of functional neutrophils, often less than 1,000 cells/mL. The presence of fever in this patient population should be considered an emergency, blood and urine cultures should be performed and broad-spectrum antibiotic coverage initiated. These patients often present with hepatomegaly secondary to fibrosis, which can lead to liver failure. This condition can result in progressive neurologic or respiratory symptoms caused by clumping and sludging of blasts in small blood vessels. Pulmonary manifestations result from leukemic infiltration of alveoli and pulmonary parenchyma, resulting in pulmonary edema, respiratory failure, and often pulmonary hemorrhage. Compared with other myeloid blast cells, monoblasts have increased adhesiveness, motility, and potential for tissue invasion. Patients often present with bruising, petechiae, epistaxis, gingival bleeding, or menorrhagia. It can present as either leukemic blasts in the spinal fluid or as chloromas with associated neurologic findings. This improvement has been accomplished by a number of factors including enrollment of children into clinical trials, dose intensification, and improved supportive care. These interventions have transformed a disease that was once uniformly fatal into one that is potentially curable. Development of chemotherapeutic regimens was based on the Goldie-Coldman hypothesis, which stated that the early use of mechanistically rational combinations of non­cross-resistant drugs delivered simultaneously and in sequential rotation would provide a more potent antileukemic effect. Induction Therapy Historical Perspective-Introduction of Cytarabine and the Anthracyclines. Since early trials utilizing cytarabine and daunorubicin, improvement of remission induction rates have centered on concepts of dose intensification, prolonged exposure to chemotherapeutic agents, and intensive timing of drug delivery. A series of international trials have been implemented to test all of these concepts of improving remission-induction rates. Dose Intensification During Induction Chemotherapy the success of the "7 + 3" combination regimen led to variations that attempted to intensify the 7 + 3 backbone. Dose intensification of anthracyclines has proven difficult because cumulative doses of 375 mg/m2 are associated with an increased risk of cardiotoxicity. Cardiac failure occurred only from the third course of chemotherapy onwards (minimum anthracycline exposure of 300 mg/m2), with 78% (7/9) occurring in conjunction with sepsis as a terminal event. These findings have led to aggressive cardiac monitoring and investigation into and testing of cardioprotectant agents. These regimens used identical doses of cytarabine and daunorubicin and tested the substitution of etoposide for thioguanine. Early adult studies performed by the Eastern Cooperative Oncology Group demonstrated that without postremission therapy, nearly all patients will relapse. The authors postulated that the maintenance chemotherapy resulted in the selection of a resistant leukemic clone. This study randomized children to receive 18 months of maintenance therapy with low-dose mercaptopurine and cytarabine versus intensive postremission therapy alone.

B: Axial image reviewed at soft tissue windows shows high attenuation regions (arrows) corresponding to calcification within the lung metastases in a different patient allergy medicine that makes you sleepy buy cheap desloratadine 5 mg online. Thallium-201 has shown value in evaluating tumor response to chemotherapy allergy shots weekly purchase desloratadine 5 mg without prescription, but has not gained widespread application allergy and immunology fellowship discount desloratadine 5 mg without prescription. The placement of the biopsy site relative to the location of the tumor and the anatomic structures of the patient is also of critical importance allergy testing atlanta desloratadine 5 mg visa. Generally allergy forecast for houston generic desloratadine 5 mg mastercard, if a malignant bone tumor is suspected, an excisional biopsy is rarely, if ever, utilized. This is due to the fact that the tumor is often large at presentation and that neoadjuvant therapy is usually appropriate prior to definitive resection. If the lesion is most likely benign based upon the preoperative history, physical examination, and imaging studies, then at the time of excision a frozen section should be obtained. Primary excision of an expendable bone should only be considered by an experienced musculoskeletal oncologist. Expendable bones may include a rib, clavicle, sternum, ilium, scapular body, and perhaps, distal ulna. Most bone tumors of uncertain biologic potential, where there is a significant suspicion for malignancy, are biopsied via an incisional approach. It is strongly recommended that the biopsy be performed by the surgeon who will perform the definitive resection so that the biopsy tract can be ellipsed within the planned surgical incision. This can be conducted using a local anesthetic, which reduces the cost of the procedure. Accordingly, deep deployment of the needle within the tumor is unnecessary and likely to lead to problems such as deep contamination and bleeding. Again the needle biopsy site must be carefully planned so that it may be excised at the time of definite resection. Core biopsies are minimally invasive, can be performed under local anesthesia, maintain the architecture of the tissue, and can obtain adequate specimen for advanced studies. Since the final diagnosis should not be based on the frozen section, the patient must wait until the results are finalized, which may take several days if special studies are necessary. If the specimen is indeterminate, which can occur in 25% to 33% of cases, even at experienced centers,312 then a delay will most definitely occur. However for suspected bone malignancies, it is usually recommended that they be performed in the operating room. Generally speaking, longitudinal incisions are the rule since transverse incisions potentially contaminate flap planes and can compromise neurovascular structures. During the approach to the tumor, no flaps should be developed to minimize contamination. The area where the tumor is most superficial is preferable unless other factors, such as an overlying vessel or nerve, preclude this option. Furthermore, the preoperative imaging may suggest that a specific area within the tumor may be more diagnostic. A frozen section must be obtained to determine if diagnostic tissue has been retrieved, but not to establish the definitive diagnosis. Careful communication with the pathologist is essential preoperatively to clarify the amount of tissue necessary for special studies and any special processing of the tissue. Formaldehyde fixes the tissue, preventing the application of conventional cytogenetics and some molecular tests. A trephine is usually adequate but if a larger window is required it is imperative that it be round or oval to minimize stress risers. A pituitary rongeur may then be used to retrieve tissue from within the medullary canal. In such cases, a drain must be placed, in line with the incision distally, and sewn in place. While their use provides for a bloodless approach, they must be let down prior to closure to assure adequate hemostasis. If used, the limb should not be exsanguinated to minimize the risk of tumor embolus. Classification and Staging Tumor extent (local and systemic) as well as malignant potential must be taken into account when classifying and staging bone tumors. Surgical approaches are a function of the osteosarcoma subtype, as well as the location and extent of disease at the time of initial diagnosis. The successful management of osteosarcoma has evolved into a multimodality approach. Advances in chemotherapy have significantly improved survival, and surgical extirpation generally occurs after a course of neoadjuvant chemotherapy. It is of paramount importance that resumption of chemotherapy not be delayed postoperatively as a delay beyond 2 to 3 weeks has been associated with an increased risk of death. This, in combination with improved neoadjuvant therapy, has enabled the oncologic surgeon to obtain local control rates equivalent to amputation. However, in severe cases, where limb salvage may compromise the oncologic outcome, amputation is mandated. Because of the complexity of the musculoskeletal system, different reconstructive options are performed depending upon the site of involvement. Generally, bone tumors arise in the distal femur, proximal tibia, proximal humerus, proximal femur, and the diaphyses of long bones. Types of Reconstruction Conceptually, reconstruction involves rebuilding the skeletal and soft tissue defect to enable optimal function for the patient. The main reconstructive options include autogenous bone grafts, structural bone allografts (intercalary or osteoarticular), and metallic endoprosthetics. Allografts and endoprosthetics may be used in conjunction as a composite reconstruction. Which technique is employed remains a function of the location of the tumor, age of the patient, and types of adjuvant therapies employed. Large structural allografts and endoprosthetics should generally be reserved for children older than 8 years. Nonvascularized autografts from the pelvis or other sites may be used in a limited fashion for relatively small defects and work well in children. Vascularized autografts such as the fibula are attractive because, when successful, the graft incorporates and even may remodel itself secondary to the forces exerted across it. The major drawback to allografts is difficulty incorporating with the host bone (nonunion) and fracture. Infections can occur in 10% to 15% of allografts323,325,329,334,335,336 and nonunion at the osteosynthesis site in 10% to 25% of cases. Augmentation of the allograft with a vascularized fibula, while adding its own set of potential complications may facilitate osseous integration of the structural graft thereby preventing the inherent problems associated with allografts. In select cases, a combination of vascularized auto- and allografting techniques may be optimal. Infections are a significant risk with endoprosthetics as well, with rates ranging from 0% to 35%. The durability of any endoprosthesis is subject to a variety of influences but the anticipated event-free 5-year survival for proximal femur reconstructions approaches 90%, while for the distal femur is about 60% and the proximal tibia just over 50%. Improved metallurgy has resulted in a significant reduction in metal fatigue and failure of the implants. Articulating, moving components need revision at a rate in direct relation to the cyclical loading of the prosthesis. Sometimes failure can be catastrophic, as can be seen with late infections, necessitating a delayed amputation. Expandable prosthetics are available with multiple, varying mechanism for expansion. Stress shielding and mechanical loosening are compounded by the continued diametrical growth of the host bone. While revision surgery is possible, the resultant bone stock for refixation can be quite tenuous. Modular components are now available for both pediatric and adult patients making the delay for customization the exception. The use of expandable prosthesis is a contentious topic and is influenced by cultural factors. More biologic reconstructive options, as discussed subsequently, are preferred by some surgeons, in the best interest of their patients, and yet the cosmetic considerations, which can be so heavy influential in some societies, is a counterargument endorsed by others. For metallic prosthesis, newer cementless, porous ingrowth systems have been developed346,363,364 but have not yet replaced cement in most centers. A novel prestress compliant fixation device, with encouraging early results, is also currently available that obviates the need for long intramedullary stems, thereby avoiding stress shielding. Arthrodesis remains an option in limb preservation surgery, but it is utilized with diminishing frequency as endoprostheses and allografts have improved. The advantage to fusion is that once healed the construct is very durable and may endure heavy labor. The procedure may be better tolerated in the upper rather than the lower extremity,380 with perhaps the exception of the ankle in select cases. Reconstruction as a Function of Location For tumors of the shoulder and proximal humerus, limb salvage is generally possible with preservation of the neurovascular structures. One unique reconstructive option for the proximal humerus is the clavicula pro humero whereby the clavicle is disarticulated from the manubrium and rotated on its vascular pedicle and fused to the remaining distal humerus providing a very stable and durable reconstruction. The middle and proximal fibula, rib, clavicle, scapular body, and iliac wing can forgo reconstruction with good functional results. In the pelvis, for iliac wing resections involving the sacroiliac joint and/or posterior column (Zone I), autografts, either non- or vascularized, can be employed to reconnect the supra-acetabular pelvis to the sacrum although reconstruction is not always necessary. External hemipelvectomy (hind quarter amputation) historically was the only surgical option. When no reconstruction is performed, the space between the hip and residual pelvis/sacrum results in significant limb shortening (up to 4 inches) and poor function, albeit better than external hemipelvectomy. An attempt at creating a sling from synthetic material to prevent proximal migration, which is subsequently augmented by scarring, may assist in minimizing limb length inequality. Saddle endoprosthetic, allograft-hip arthroplasty composites, and complete endoprosthetic replacement have all been performed. If internal hemipelvectomy is to be attempted, the goal must be an adequate resection of the tumor, which can prove to be quite difficult. Special Considerations for the Skeletally Immature the skeletally immature patient presents a particular challenge in that the reconstruction must be dynamic in order to accommodate future growth when a physis is sacrificed. Because osteosarcoma generally arises in the child and adolescent, this can become a significant issue. In girls, the growth spurts occur in pre- and early adolescence, while in boys it happens later. Most of the growth in the lower extremity is provided for by the physes about the knee (distal femur approximately 40%, proximal tibia approximately 30%) while the upper femur and lower tibia have modest contributions of about 15% each. Limb lengthening via distraction osteogenesis is also an option,405,406,407 but there remains concern in utilizing this complex technique concurrently with P. Intrinsic reconstructions such as rotationplasty and tibial turn up-plasties are particularly attractive in the skeletally immature patient, especially in children younger than 8 years, who will experience a significant amount of growth. Most commonly, this is done for resection of the knee, where the ankle subsequently functions as a knee joint. Accordingly, many children and their families adjust very well to their new appearance and function. Noncontiguous disease ("skip lesions") proximal to the main tumor, if not detected, can result in recurrence within the stump in up to 20% of cases. With the careful screening preformed by an experienced orthopaedic oncologist, contemporary limb salvage surgery does not appear to impart a survival disadvantage. Nevertheless, if the margins are precarious at the preoperative staging evaluation, then amputation is necessary. Complications are far more frequent in limb salvage patients than in those who undergo amputation. Furthermore, patients that either present with a pathologic fracture, or fracture during induction chemotherapy, may be poor candidates for limb salvage surgery. The age of the patient, location of the tumor, presence or absence of pathologic fracture, and the desires of the patient and family must be considered carefully. Accordingly, aggressive reconstruction with vascular and/or nerve grafting as necessary should be done to save even limited hand and wrist function. In the lower extremity, external hemipelvectomy leads to a particularly poor functional result. A hip disarticulation at least permits improved sitting although prosthetic use remains poor. For tumors above the proximal tibia, limb salvage with one of the above techniques is preferable to amputation and can potentially give equally functional results. Patients undergoing above the knee amputation have increased energy expenditure compared with those undergoing endoprosthetic reconstruction. Ifosfamide (I) with444 or without261,445 etoposide (E) have shown promising activity, although their role in improving outcome has not been adequately evaluated. Although early nonrandomized trials suggested that the addition of chemotherapy improved the outcome for patients with osteosarcoma,433,434,435,436,437 some investigators were concerned that the reported improved outcome was related to patient selection, stage migration (related to the introduction of computed tomography), or improved surgical techniques. The results of that trial suggested that the natural history of osteosarcoma had indeed changed. Two subsequent controlled randomized trials confirmed the importance of chemotherapy administration for patients with osteosarcoma. In an effort to increase the number of patients able to undergo limb-sparing procedures, investigators at Memorial Sloan Kettering Cancer Center started using preoperative chemotherapy. The administration of chemotherapy allowed extra time for construction of prosthetic devices and also had the theoretical advantage of treating presumed micrometastatic disease.

In contrast allergy symptoms for over a week 5 mg desloratadine with mastercard, the young adult form is associated with a higher socioeconomic status in industrialized countries allergy forecast kingston ontario purchase desloratadine 5 mg with visa. The disease may represent a common result of multiple pathologic processes that include viral infection and exposure of a genetically susceptible host to a sensitizing agent allergy forecast brenham tx desloratadine 5 mg order overnight delivery. With the advent of widely available immunohistochemical staining allergy symptoms hay fever symptoms order desloratadine overnight delivery, the latter entities are usually easy to exclude allergy medicine and weed purchase desloratadine us. The classic Reed-Sternberg cell is large (15 to 45 m in diameter), with abundant slightly basophilic cytoplasm and two nuclei or two nuclear lobes. These cells have a thick nuclear membrane, pale chromatin, and two large eosinophilic nucleoli (one in each nuclear lobe). In some patients, Hodgkin cells may be highly pleomorphic raising the differential diagnosis with high-grade sarcomas and diffuse large cell lymphomas with anaplastic features. These are typically mononuclear cells with markedly convoluted and lobated nucleus (popcorn cells), thin nuclear membrane, pale chromatin, and one-to-several small basophilic nucleoli. Four histologic subtypes are further included in this category based on tissue architecture, the presence of fibrosis, and the features of the associated inflammatory infiltrate. The presence of nodularity is essential in the differential diagnosis with T-cell­rich Bcell lymphoma, which has an exclusively diffuse growth pattern. Cellular nodules are surrounded by dense fibrous bands (hematoxylin and eosin; 8×). This process has a striking propensity to involve the lower cervical, supraclavicular, and mediastinal lymph nodes. Because of the abundance of collagen, the radiographic appearance of these lesions (particularly in the mediastinum) may only slowly return to normal, even when the patient is responding to therapy. The tumor usually has a diffuse or a vaguely nodular growth pattern and lacks significant associated fibrosis. The inflammatory background consists of lymphocytes, plasma cells, eosinophils, and histiocytes. Fine interstitial fibrosis may be seen, and focal necrosis may be present but usually is not marked. This subtype is observed in approximately 30% of patients, is more common in children aged 10 years or younger,73,74 and frequently presents as advanced disease with extranodal involvement. The presence of numerous, large, bizarre, malignant cells, many Reed-Sternberg cells, and few lymphocytes P. Affected lymph nodes are firmer than inflammatory nodes, they feel rubbery, and may be sensitive to palpation if they have grown rapidly. In younger children, mediastinal lymphadenopathy may be difficult to distinguish from a large, normal thymus. Primary disease presenting in a subdiaphragmatic site is rare and occurs in only approximately 3% of cases. Systemic Symptoms Nonspecific systemic symptoms may include fatigue, anorexia, and slight weight loss. Three specific constitutional (B) symptoms correlate with prognosis: unexplained fever with temperatures above 38. Although it is not considered one of the classic "B" symptoms, some studies suggest that it has a similar prognostic significance and confers a poor prognosis. Laboratory Profile Hematologic and chemical blood parameters show nonspecific changes that may correlate with disease extent. Abnormalities of peripheral blood counts may include neutrophilic leukocytosis, lymphopenia, eosinophilia, and monocytosis. At the onset of disease, the absolute lymphocyte count is usually normal in children,84 although adults with extensive disease commonly have lymphopenia. Anemia may indicate the presence of advanced disease and usually results from impaired mobilization of iron stores. The erythrocyte sedimentation rate, serum copper, and ferritin levels may be elevated, reflecting activation of the reticuloendothelial system. Furthermore, soft tissue sarcomas and germ cell tumors can present in the neck or mediastinum, as can metastatic adenopathy from other primary tumors. A more difficult problem is that of a mediastinal mass that must be differentiated from normal thymus in an otherwise asymptomatic patient. A careful physical examination with assessment of all node-bearing areas, including Waldeyer ring, is essential, with measurement of enlarged nodes so changes can later be quantified. Symptoms of a large mediastinal mass Superior Vena Cava syndrome: Dyspnea, facial swelling, cough, orthopena, and headache Tracheal or bronchial compression: Cough, dyspnea, and orthopnea Physical examination Lymph nodes Location and size Tonsils Lung auscultation Abdomen Laboratory tests Complete blood count Biochemistry profile Symmetry, size and nodularity Stridor and wheezing Hepatomegaly and splenomegaly Anemia, leukocytosis, and lymphopenia Elevated lactate dehydrogenase and low albumin. Renal and hepatic function studies prior to starting chemotherapy to determine need for dose adjustments and tolerability. Elevation of markers of inflammation at diagnosis can be followed for response to therapy. Gallium-67 scintigraphy Technetium-99 bone scintigraphy Biopsy Bone marrow Metabolic activity of involved nodes and organs. Patients are considered to have "bulky" mediastinal lymphadenopathy if it measures greater than or equal to 33% of the maximum intrathoracic cavity. Liver size and liver function studies are also unreliable indicators of hepatic disease. Organ size and degree of involvement do not strictly correlate because tumor deposits may be less than 1 cm in diameter and not visualized by diagnostic imaging modalities. The pattern of infiltration in the bone marrow may be diffuse or focal and is often accompanied by reversible marrow fibrosis. B symptoms include fever exceeding 38°C for 3 consecutive days, drenching night sweats, and an unexplained loss of at least 10% of body weight over 6 months. Substage E denotes minimal extralymphatic extension from contiguous nodal disease. This shift has taken place because standard-dose irradiation and alkylator-based chemotherapy have significant treatment effects, which can often be attenuated by combined-modality approaches incorporating more limited chemotherapy with reduced dose limited volume radiation therapy. Multiple clinical trials have addressed the additive value of involved-field radiation to multiagent chemotherapy, P. Selection of patients for radiation avoidance, integration of modern radiotherapeutic approaches for improved conformal delivery of dose, and further reduction in the volume of treatment remain important questions for study in the context of the excellent disease control rates already achieved with traditional radiation techniques. Understanding the principles and approaches of radiation therapy employed in existing and published studies as well as the opportunities for improvement in the delivery of this modality will be important for pediatric oncologists and radiation oncologists as we continue to make progress in this highly curable disease. Local control rates remain high, 89% to 95%, despite the lower radiation dose and reduced intensity of systemic therapy. Dose elimination, dose reduction, and dose escalation are all used in modern clinical trials, but the approach from one trial is not transferable to another. It is important to understand the methods and timing of response assessments as one compares each clinical trial or treats with its specific approach Table 22. Volume Selection Significantly less investigated is the role of volume reduction in radiation therapy treatment fields. In the combined-modality era, treatment volumes no longer need to account for the potential spread of all microscopic disease, focusing more on areas of large volume disease or poor response. The definition of a standard involved field is not standard at all, but attempts have been made to standardize it. The importance in moving beyond standard involved fields is not to improve the local control rates (which already exceed 90%) but to further reduce late effects from radiation therapy. The simplest method for reduction in end organ toxicity such as hypothyroidism or secondary breast cancer is to avoid treating the organ at risk. This in conjunction with modern imaging will continue to reduce exposure of normal tissue to radiation while maintaining equivalent local disease control rates. Radiotherapy Techniques Radiation simulation is the process of positioning the patient in a consistent, comfortable, and reproducible position for daily therapy. This improved knowledge of specific doses to an organ may help better understand end organ toxicities that result from radiation as well as allowing for avoidance when possible. Nodal regions and other tissues that need treatment as well as normal tissues for avoidance or dose P. These targets and normal tissues (referred to as contours) are then rendered as 3-dimensional shapes. Treatment beams are then created with the aid of the medical physicist in the computer environment to treat the areas at risk and avoid adjacent normal tissues. Beam arrangements are often from the anterior and posterior but are not limited to these orientations; current clinical trials are investigating the safety and benefit of more complex beam arrangements. Before treatment of disease in the pelvic region, it may be necessary to transpose the ovaries medially or use a testicular shield to maintain hormone production and fertility. Treatment radiation dose levels are shown as a percent of the total prescribed dose. Higher energies may be desired when treating the abdominal region in particularly thick patients. Treatment regions may need to be separated by a 1- to 2-week break to ensure bone marrow recovery. Its integration in the combined-modality therapy approach continues to evolve and also continues to become more complex. It is important to include the radiation oncologist as part of the treatment team from staging through response to address radiation-specific issues that will alter the treatment process, dose, and volumes. Only with this degree of integration and cooperation will patients receive the full benefit of risk-adapted therapy. The agents should differ in the mechanism of antineoplastic activity, thereby targeting different cellular or biochemical events and preventing development of resistance. Toxicities of the agents should not overlap, so that each drug can be administered at full single-agent dose. However, concerns regarding potential cardiopulmonary sequelae have restricted its use as the sole regimen in pediatric patients. Treatment Results Optimal therapy involves a multidisciplinary approach from the time of diagnosis. This is particularly important, as treatment decisions are currently based on risk features present at diagnosis, including the presence of B symptoms, stage, peripheral nodal and/or mediastinal bulk, and number of involved nodal regions. Assignment of stage and treatment are best determined after the pediatric and radiation oncologists have had the opportunity to examine the patient and review staging study results, preferably with simultaneous input from a diagnostic imager. In this way, a consistent plan for chemotherapy and radiation therapy can be presented to the family by all health care providers and reviewed periodically after response evaluations. Combined-Modality Therapy From the 1960s to 1980s, standard-dose (35 to 44 Gy), extended-volume radiation therapy was commonly used in conjunction with combination chemotherapy to enhance local tumor control. The observation of substantial late effects in children who received high-dose radiotherapy provided the impetus for studies evaluating combinedmodality treatments prescribing low-dose (15. Systemic chemotherapy also avoids the potential long-term musculoskeletal complications, organ dysfunction, and solid tumor malignancies associated with high-dose, extended-field radiation therapy. Acute hematologic and infectious toxicities related to these regimens appear acceptable, but long-term cardiopulmonary sequelae have not been evaluated. Evaluation of the efficacy of chemotherapy-only treatment regimens has been difficult because most reports describe outcome after nonrandom treatment assignments in small clinically staged cohorts. Only a few randomized pediatric trials have compared treatment outcome after chemotherapy alone with combined-modality therapy. North American pediatric cooperative group randomized trials have also prospectively compared treatment with combined-modality therapy to chemotherapy alone. However, analysis based on treatment actually delivered showed a superior outcome in patients treated with chemotherapy and radiation therapy. Patients achieving a complete response to chemotherapy were eligible for randomization to receive low-dose, involved-field radiation or no further therapy. A significantly higher number of relapses among patients treated with chemotherapy alone resulted in early closure of the study. Estimates for overall survival are not different between the randomized groups due to successful salvage therapy after relapse, but follow-up of the cohort is early. The estimated 5-year disease-free survival was significantly lower in the 222 patients treated with chemotherapy alone compared with the 758 patients treated with combined-modality therapy (88% vs. Again, overall survival was not significantly reduced due to the effectiveness of retrieval therapy. These results prompted a recommendation for omission of radiation therapy only for early stage favorable risk patients. The advantage of this approach is the elimination of radiation-associated adverse sequelae including musculoskeletal under-development, cardiac dysfunction, and solid tumor induction. Chemotherapy-alone treatment protocols rely on higher cumulative doses of agents with established dose-related toxicity, however, especially alkylating agent chemotherapy, which may contribute to acute and late treatment morbidity. Bulky mediastinal lymphadenopathy is designated when the ratio of the maximum measurement of mediastinal lymphadenopathy to intrathoracic cavity on an upright chest radiograph equals or exceeds 33%. Risk factors considered in other studies include the number of involved nodal regions, the presence of hilar adenopathy, the size of peripheral lymphadenopathy, and extranodal extension. Several trials have reduced the dose of radiation in patients achieving a favorable response to chemotherapy. Conventional therapy prescribes non­cross-resistant chemotherapy on a twice-monthly schedule for a total of 6 months. Chemotherapy is administered at weekly intervals for a period of 3 to 5 months during which myelosuppressive agents are alternated with nonmyelosuppressive agents. Consolidative radiation therapy, usually standard-dose in the adult setting, is administered to sites of bulky or residual disease. Preliminary results of North American pediatric cooperative groups support the feasibility of this approach combined with low-dose radiation therapy. Longterm results of the German Pediatric Oncology Group trials indicate that event-free survival has not been compromised with reduction from six to four chemotherapy cycles in children with these "intermediate" risk features. The presence of four to five of these pretreatment factors correlated with a particularly poor 5-year disease-free survival and survival of only 49% and 72%, respectively. Treatment and ultimate prognosis after relapse is largely dependent on the initial therapy type and time of relapse. As many as 50% to 80% of patients who relapse after radiation therapy alone can be salvaged with chemotherapy or combined-modality therapy. Standard multiagent chemotherapy and radiation therapy may salvage 40% to 50% of children with 1-year or longer initial remissions, but subsequent treatment sequelae, including second malignancies, may reduce ultimate survival.

Generic desloratadine 5 mg mastercard. 🤔WALMART SELLS REBORN BABIES?😃 REBORN REACTIONS!😆.

References

• Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the united kingdom. Arch Dermatol 2003;139(11):1425-9.
• Ricker K, Lehmann-Horn F, Moxley RT. Myotonia fluctuans. Arch Neurol. 1990;47:268-272.
• Dickerson N, Horton P, Smith S, et al. Clinically signifi cant central venous catheter infections in a community hospital. Association with type of dressing. J Infect Dis. 1989;160:720-721.
• Milkowitz DJ, Hooley JM: Developing family psychoeducational treatments for patients with bipolar and other severe psychiatric disorders: a pathway from basic research to clinical trials, Marital Fam Ther 24:419-435, 1998.
• Albanese J, Arnaud S, Rey M, Thomachot L, Alliez B, Martin C. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. Anesthesiology. 1997;879(6): 1328-1334.
• Horton CE, Dean JA: Reconstruction of traumatizing acquired defects of the phallus, World J Surg 14:757n762, 1990.
• Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler- Najjar, Dubin-Johnson, Rotor syndrome). Best Pract Res Clin Gastroenterol. 2010;5:555-571.
• Seward JB, Khandheria BK, Oh JK, et al: Transesophageal echocardiography: Technique, anatomic correlations, implementation, and clinical applications, Mayo Clin Proc 63:649-680, 1988.